IL1A and chronic obstructive pulmonary disease: Given that both IL-1α and IL-1β are expressed in COPD and during episodes of acute exacerbation[12], therapies targeted at the receptor rather than the individual ligands may be more relevant for limiting inflammation and exacerbations in COPD.